The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Costimulation Blockade with Belatacept in Renal Transplantation
Open accessAbstract
BACKGROUND: Renal transplantation is the standard of care for patients with end-stage renal disease. Although maintenance immunosuppression with calcineurin inhibitors yields excellent one-year survival, it is associated over the long term with high rates of death and graft loss, owing in part to the adverse renal, cardiovascular, and metabolic effects of these agents. The use of potentially less toxic agents, such as belatacept, a selective blocker of T-cell activation, may improve outcomes. METHODS: We randomly assigned renal-transplant recipients to receive an intensive or a less-intensive regimen of belatacept or cyclosporine. All patients received induction therapy with basiliximab, mycophenolate mofetil, and corticosteroids. The primary objective was to demonstrate the noninferiority of belatacept over cyclosporine in the incidence of acute rejection at six months (with an upper bound of the 95 percent confidence interval around the treatment difference of less than 20 percent). RESULTS: At six months, the incidence of acute rejection was similar among the groups: 7 percent for intensive belatacept, 6 percent for less-intensive belatacept, and 8 percent for cyclosporine. At 12 months, the glomerular filtration rate was significantly higher with both intensive and less-intensive belatacept than it was with cyclosporine (66.3, 62.1, and 53.5 ml per minute per 1.73 m2, respectively), and chronic allograft nephropathy was less common with both regimens of belatacept than with cyclosporine (29 percent, 20 percent, and 44 percent, respectively). Lipid levels and blood-pressure values were similar or slightly lower in the belatacept groups, despite the greater use of lipid-lowering and antihypertensive medications in the cyclosporine group. CONCLUSIONS: Belatacept, an investigational selective costimulation blocker, did not appear to be inferior to cyclosporine as a means of preventing acute rejection after renal transplantation. Belatacept may preserve the glomerular filtration rate and reduce the rate of chronic allograft nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Wolfe, R. A., Ashby, V. B., Milford, E. L., Ojo, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,371
The Banff 97 working classification of renal allograft pathology
Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00299.x · Cited by 3,033
Self-citationThe Natural History of Chronic Allograft Nephropathy
Nankivell, B. J., Borrows, R. J., Fung, C. L.-S., O'Connell, P. J., Allen, R. D. M., & Chapman, J. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020009 · Cited by 1,949
The Quality of Life of Patients with End-Stage Renal Disease
Evans, R. W., Manninen, D. L., Garrison, L. P., Hart, L. G., Blagg, C. R., Gutman, R. A., Hull, A. R., & Lowrie, E. G. (1985) · New England Journal of Medicine · doi:10.1056/nejm198502283120905 · Cited by 1,183
Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report
Opelz, G., & Döhler, B. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00325.x · Cited by 1,081
Cancer after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D. T., & Wang, C. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00450.x · Cited by 1,071
Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035075 · Cited by 1,058
Self-citation
Cited by
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
CD28 Costimulation: From Mechanism to Therapy
Esensten, J. H., Helou, Y. A., Chopra, G., Weiss, A., & Bluestone, J. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.020 · Cited by 937
Vincenti, F., Charpentier, B., Vanrenterghem, Y., Rostaing, L., Bresnahan, B., Darji, P., Massari, P., Mondragon‐Ramirez, G. A., Agarwal, M., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.03005.x · Cited by 957
Self-citationAutosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
Schubert, D., Bode, C., Kenefeck, R., Hou, T. Z., Wing, J. B., Kennedy, A., Bulashevska, A., Petersen, B.-S., Schäffer, A. A., Grüning, B. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3746 · Cited by 832
Long-Term Survival after Kidney Transplantation
Hariharan, S., Israni, A. K., & Danovitch, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2014530 · Cited by 664
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Rejection of the Kidney Allograft
Nankivell, B. J., & Alexander, S. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0902927 · Cited by 605
Durrbach, A., Pestana, J. M., Pearson, T., Vincenti, F., Garcia, V. D., Campistol, J., Del Carmen Rial, M., Florman, S., Block, A., Di Russo, G., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03016.x · Cited by 570
Self-citationCarosella, E. D., Rouas-Freiss, N., Roux, D. T.-L., Moreau, P., & LeMaoult, J. (2015) · Advances in Immunology · doi:10.1016/bs.ai.2015.04.001 · Cited by 395
Bour‐Jordan, H., Esensten, J. H., Martinez‐Llordella, M., Penaranda, C., Stumpf, M., & Bluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01011.x · Cited by 391
Fishbein, T. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804605 · Cited by 366
Calcineurin inhibitors: 40 years later, can’t live without
Azzi, J. R., Sayegh, M. H., & Mallat, S. G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1390055 · Cited by 337
Adeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate Muscle
Penaud-Budloo, M., Le Guiner, C., Nowrouzi, A., Toromanoff, A., Chérel, Y., Chenuaud, P., Schmidt, M., von Kalle, C., Rolling, F., Moullier, P., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00649-08 · Cited by 317
An Enigmatic Tail of CD28 Signaling
Boomer, J. S., & Green, J. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a002436 · Cited by 283
CTLA4Ig: Bridging the Basic Immunology with Clinical Application
Bluestone, J. A., St. Clair, E. W., & Turka, L. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.001 · Cited by 276
Jordan, S. C., Choi, J., Kim, I., Wu, G., Toyoda, M., Shin, B., & Vo, A. (2017) · Transplantation · doi:10.1097/tp.0000000000001452 · Cited by 260
Update on Islet Transplantation
McCall, M., & James Shapiro, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007823 · Cited by 226
The changing face of heart transplantation
Hunt, S. A., & Haddad, F. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.020 · Cited by 225
Baker, R. J., Mark, P. B., Patel, R. K., Stevens, K. K., & Palmer, N. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0553-2 · Cited by 211
A comprehensive review of immunosuppression used for liver transplantation
Mukherjee, S., & Mukherjee, U. (2009) · Journal of Transplantation · doi:10.1155/2009/701464 · Cited by 140
Moassesfar, S., Masharani, U., Frassetto, L. A., Szot, G. L., Tavakol, M., Stock, P. G., & Posselt, A. M. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13536 · Cited by 80
Does belatacept improve outcomes for kidney transplant recipients? A systematic review
Talawila, N., & Pengel, L. H. M. (2015) · Transplant International · doi:10.1111/tri.12605 · Cited by 32
Frentsch, M., Japp, A. S., Dingeldey, M., Matzmohr, N., Thiel, A., Scheiflinger, F., Reipert, B. M., & de la Rosa, M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14757 · Cited by 17
Metadata
- Authors
- Vincenti, F., Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P. F., Solez, K., Hagerty, D., Levy, E., Zhou, W., Natarajan, K., & Charpentier, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-08-25
- Volume
- 353
- Issue
- 8
- Pages
- 770-781
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2107346812
- Cited by
- 861
- References
- 29
- FWCI
- 34.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.